Background Neurotrophic keratopathy (NK) is a rare degenerative corneal disease caused by impaired trigeminal innervation, resulting in reduced corneal sensation, impaired epithelial healing, ulceration, and risk of perforation or vision loss. Corneal innervation is essential for protective reflexes, epithelial maintenance, and ocular surface homeostasis. Conventional medical therapies may promote epithelial healing but do not directly restore corneal innervation. Corneal neurotization (CN) has emerged as a surgical strategy in which healthy donor sensory axons are transferred to denervated corneas to provide innervation. Multiple procedural variations now exist, including differences in donor nerve selection, graft use, and methods of limbal nerve insertion. A broad variety of NK etiologies is also being treated, including congenital, infectious, tumor, or other causes. However, published evidence remains limited by small case series, heterogeneous surgical methods, short follow-up periods, and inconsistent outcome reporting.

Objective To address the need for standardized long-term outcome data in CN, we established the Corneal Neurotization Assessment (CorNeA) Registry, an international multicenter observational registry designed to evaluate patients undergoing CN.

Methods The CorNeA Registry captures demographic characteristics, disease etiology, surgical technique, and longitudinal ocular outcomes in patients with NK treated with CN. Data are recorded in REDCap and include both retrospective and prospective patient enrollment across participating centers. Patients are followed longitudinally after surgery without a predefined endpoint to permit long-term assessment of corneal sensation recovery, ulcer recurrence, and visual outcomes. At the time of reporting, the registry includes 58 patients from multiple international centers, with active expansion ongoing.

Conclusion Because NK is rare and CN remains an evolving surgical field, long-term comparative data are lacking. The CorNeA Registry provides the first international platform to characterize patient selection, procedural variation, and long-term outcomes after CN, with the goal of informing future surgical decision-making and outcome standardization.

Dr. Borschel is a paid consultant for AxoGen, Inc.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

IRB of Indiana University gave ethical approval for this work

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present work are contained in the manuscript